|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Tracon Pharmaceuticals, Inc.
| | | Phone: | (858) 550-0780 | Fax: | (858) 550-0786 | Year Established: | 2005 | Ticker: | TCON | Exchange: | NASDAQ | Main Contact: | Charles P. Theuer, M.D., Ph.D., President & CEO | | Other Contacts: | Jennifer Ellis, VP, Quality Assurance Mark Wiggins, CBO Sharon Real, Ph.D., Senior VP, Product Development Laurence Gamelin, VP, Pharmacovigilance and Safety Patricia Bitar, CPA, CFO Suzy Benedict, M.S., VP, Regulatory Affairs Bonne Adams, M.B.A., Senior VP, Clinical Operations
| | Company Description | TRACON develops targeted therapies for cancer, wet AMD and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. | |
|
|
|
|
|